[ad_1]
New Zealand science-driven company, Orbis Diagnostics has
undertaken a trial with Air New Zealand employees to
significantly accelerate the development of Orbis’
automated Covid-19 immunity testing platform which may be a
key tool in helping New Zealanders reconnect with the
world.
Orbis spokesperson Kieran Jina said the
partnership involved testing a selection of Air New Zealand
employees and is a vital step in the development and
commercialisation pathway for the
technology.
“Orbis’ immunity testing platform has
been specifically designed to accurately measure an
individual’s immunity to Covid-19 at non-laboratory,
high-volume locations like airports and point of need sites
like pharmacies and workplaces within 15 minutes,” said Mr
Jina.
“This means the level of protection a fully
vaccinated individual has gained from vaccination can be
quickly determined and correlated to the risk of infection
to make an informed assessment of whether the individual can
reduce their quarantine period without increasing the chance
of transmitting the virus.
“Having information about
a person’s immunity will be critical as everyone’s
response to vaccination is different and it’s also likely
the effectiveness of the vaccine will wear off over time.
The results obtained from the trial will be used to further
validate the use of rapid immunity testing alongside other
testing technologies in a risk-based framework that
facilitates the re-opening of our
borders.
“Supporting the gradual shifting of our
border settings isn’t the only application of the
technology. As we navigate this complex virus, it can be
used to regularly test individuals to make sure their
immunity isn’t wearing off which could signal the need for
a booster shot,” said Mr Jina.
Air New Zealand Chief
Medical Officer Dr Ben Johnston said “Air New Zealand was
thrilled to be part of the trial to verify Orbis’s
immunity testing technology. We know that when borders
reopen, measures like immunity testing may compliment the
high vaccination rates required to keep communities
safe.”
Mr Jina adds “With comparable accuracy to
the complex tests available in medical labs, each Orbis’
device is capable of taking a finger prick of blood from up
to 8 people at a time and reporting results within 15
minutes, making it a robust, cost effective, scalable, and
practical solution to support the gradual shifting of border
settings.
“In addition to the Air New Zealand study,
we are thrilled to be part of Sir Ian Taylor’s 151 Off the
Bench trial, measuring his immunity and protection to
Covid-19 on the day of his departure from New
Zealand.
“The Air New Zealand trial and work with
Sir Ian advances our partnership with the world’s leading
global identity company IDEMIA to develop and deploy a
complete immunity testing solution for the travel industry
for COVID-19 applications and beyond,” said Mr
Jina.
About Orbis
Diagnostics:
Orbis Diagnostics’ mission is to make
complex medical testing simple and accessible whenever and
wherever needed to overcome some of the world’s biggest
health challenges. Built on a diagnostic platform, Orbis’
technology is specifically designed to deliver highly
accurate, medical grade testing into high-volume,
non-laboratory environments, enabling critical decisions to
be made quickly, with confidence.
The first
application of Orbis’ platform is an on-demand immunity
test capable of accurately measuring an individuals’
immunity to Covid-19 and reporting results within 15
minutes. This application will be a key component of
international border frameworks to facilitate safe travel,
solving a potentially long-lasting issue. Through its
partnerships with governments and leading biometrics
company, IDEMIA, Orbis will deploy a complete quantitative
immunity test solution at points of travel around the
world.
[ad_2]
Source link